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ABSTRACT
Tolvaptan is a selective V2-receptor antagonist primarily metab-
olized by CYP 3A. The present study investigated the hepatocel-
lular disposition of tolvaptan and the generated tolvaptan
metabolites, DM-4103 and DM-4107, as well as the potential for
drug-drug interactions (DDIs) with metabolic and transport pro-
teins in sandwich-cultured human hepatocytes (SCHH). Tolvaptan
was incubated with SCHH and quantified by liquid chromatography–
tandem mass spectrometry. Pioglitazone, verapamil, MK-571, and
elacridar were used as inhibitors to investigate mechanisms of
transport andmetabolism of tolvaptan andmetabolites. Taurocholate
(TCA), pravastatin, digoxin, and metformin were used as transporter
probes to investigate which transport proteins were inhibited by
tolvaptan and metabolites. Cellular accumulation of tolvaptan (0.15–50
mM), DM-4103, and DM-4107 in SCHHwas concentration-dependent.
Tolvaptan accumulation (15 mM) in SCHH was not altered markedly
by 50 mM pioglitazone, verapamil, MK-571, or 10 mM elacridar. Coincu-
bation of tolvaptan with pioglitazone, verapamil, MK-571, and elacridar
reduced DM-4107 accumulation by 45.6, 79.8, 94.5, and 23.0%, respec-
tively, relative to control. Coincubation with increasing tolvaptan con-
centrations (0.15–50mM)decreasedTCA (2.5mM)cell+bile accumulation
and the TCA biliary excretion index (BEI; from 76% to 51%), consistent
with inhibition of the bile salt export pump (BSEP). Tolvaptan (15 mM)
had no effect on the cellular accumulation of 2.5 mM pravastatin or
metformin. Digoxin cellular accumulation increased, and the BEI
of digoxin decreased from 23.9 to 8.1% in the presence of 15 mM
tolvaptan, consistent with inhibition of P-glycoprotein. In sum-
mary, SCHH studies revealed potential metabolic- and transporter-
mediated DDIs involving tolvaptan and metabolites.
Introduction
Tolvaptan is an orally available selective V2-receptor antagonist used to
treat hypervolemic and euvolemic hyponatremia in patients with heart
failure and refractory ascites in cirrhosis (Berl et al., 2010; Sakaida, 2014).
After oral administration, tolvaptan was absorbed readily from the gas-
trointestinal tract with an absolute bioavailability of ;50% after a 30-mg
dose, and was metabolized extensively, with;1% of the dose excreted in
the urine unchanged (Shoaf et al., 2007, 2012a). CYP3A is the main
enzyme involved in tolvaptan metabolism, primarily forming dehydro-
genated and hydroxylated metabolites (Shoaf et al., 2012b). DM-4103 and
DM-4107 are two major metabolites of tolvaptan primarily excreted in
urine and feces, respectively (Tammara et al., 1999). When [14C]tolvaptan
was administered orally to rats, biliary excretion was a predominant route
of elimination for tolvaptan and metabolites (Furukawa et al., 2011).
Hepatocyte cultures preserve whole cellular architecture and func-
tion and have been useful for understanding and estimating metabolic
clearance and hepatocellular transport (Chiba et al., 2009). In particular,
sandwich-cultured human hepatocytes (SCHH) have become a prom-
inent tool to evaluate hepatobiliary drug disposition owing to their abil-
ity to retain in vivo-like metabolic and excretory properties, some of
which are not preserved using conventional culture conditions (Swift
et al., 2010). Transport proteins, including basolateral and biliary efflux
transporters, have been shown to properly localize on the basolateral and
canalicular domains of SCHH; this allows for accurate correlation
between in vitro intrinsic biliary clearance and in vivo biliary clearance
(Liu et al., 1999; Swift et al., 2010).
Despite research characterizing the metabolism of tolvaptan, the
hepatobiliary disposition and potential interactions with hepatic
transporters have not been fully explored. Previous studies demon-
strated that tolvaptan is a substrate and an inhibitor of P-glycoprotein
(P-gp) (Shoaf et al., 2011). Our recent studies in membrane vesicles
and transfected cells revealed that tolvaptan and metabolites could
inhibit several transporters, including sodium taurocholate (TCA)
cotransporting polypeptide (NTCP), the bile salt export pump
Funding was provided by Otsuka Pharmaceutical Development and Commer-
cialization, Inc., and by the National Institutes of Health National Institute of
General Medical Sciences [Award no. R01GM041935 (K.L.R.B.)]. The content is
solely the responsibility of the authors and does not necessarily represent the
official views of Otsuka or the NIH.
Dr. M. Pan is an employee of Otsuka Pharmaceutical Development and
Commercialization, Inc. Dr. K. R. Brouwer, Ms. K. M. Freeman, and Dr. R. L. St.
Claire are employed by Qualyst Transporter Solutions, LLC. Dr. K. L. R. Brouwer is
a coinventor of the sandwich-cultured hepatocyte technology for quantification of
biliary excretion (B-CLEAR) and related technologies, which have been licensed
exclusively to Qualyst Transporter Solutions, LLC.
dx.doi.org/10.1124/dmd.115.067629.
s This article has supplemental material available at dmd.aspetjournals.org.
ABBREVIATIONS: BEI, biliary excretion index; BSEP, bile salt export pump; BSA, bovine serum albumin; DDIs, drug-drug interactions; HBSS,
Hanks’ balanced salt solution; MK-571, 3-[[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanyl-
propanoate; MRP, multidrug resistance–associated protein; NTCP, sodium taurocholate cotransporting polypeptide; P-gp, P-glycoprotein; SCHH,
sandwich-cultured human hepatocytes; TCA, taurocholate.
867
(BSEP), the multidrug resistance–associated protein 2 (MRP2),
MRP3, and MRP4 (Slizgi et al., 2016). However, the role of hepatic
transporters in the disposition of tolvaptan and metabolites has not
been identified in hepatocytes under physiologic conditions. The
ability to accurately predict the potential for transporter-mediated
drug-drug interactions (DDIs) of tolvaptan and metabolites at the
cellular level solely on the basis of membrane vesicle data remains to
be determined. The purpose of this study was to investigate the
hepatobiliary disposition of tolvaptan and generated metabolites, and
possible DDIs with hepatic metabolic and transport proteins using
SCHH.
Materials and Methods
Materials. Tolvaptan, DM-4103, and DM-4107 (purity . 99%) were
provided by Otsuka Pharmaceutical Co. (Tokyo, Japan). Stably labeled TCA
(d8-TCA)was purchased fromMartex Inc. (Minnetonka,MN). Elacridar, digoxin,
metformin, MK-571, and pravastatin were obtained from Sigma-Aldrich (St.
Louis, MO). All other chemicals were of analytical grade.
Cell Culture and Transport Studies in SCHH. Transporter-Certified
sandwich-cultured human hepatocytes (SCHH) were purchased from Triangle
Research Laboratories (lot no. HUM4059: Caucasian female; age = 17 year; body
mass index = 25.5; no tobacco, alcohol, or drug use; see Supplemental Data) and
prepared by Qualyst Transporter Solutions (Durham, NC) using cryopreserved
hepatocytes as described by Slizgi et al. (2016). On day 5 of culture, themediawas
aspirated and the SCHH were rinsed with 0.5 ml/well of standard or Ca2+-free
Hanks’ balanced salt solution (HBSS). After the second rinse, HBSS buffers were
aspirated completely and SCHHwere incubatedwith 0.5ml of standard or Ca2+-free
HBSS buffers for 10 minutes. After 10 minutes, HBSS buffers were aspirated
and the cells were incubated with standard HBSS buffer containing tolvaptan
(0.15–50 mM) and 4% bovine serum albumin (BSA) for 10 minutes. For studies
investigating possible DDIs with tolvaptan and drug-metabolizing enzymes and
transporters, tolvaptan (15 mM) was coincubated with pioglitazone (50 mM),
verapamil (50 mM), MK-571 (50 mM), or elacridar (10 mM). For studies
investigating possible DDIs of tolvaptan with hepatic transporters, tolvaptan
(15 mM) was coincubated with d8-TCA (2.5 mM), pravastatin (2.5 mM), digoxin
(2.5 mM), or metformin (2.5 mM). Dimethyl sulfoxide was used to solubilize
all compounds; the final dimethyl sulfoxide concentration was 0.2% v/v. After
incubation, the HBSS buffer was aspirated from all wells and eachwell was rinsed
three times with ice-cold standard HBSS buffer. Plates were sealed and stored
at –80C until analysis.
Sample Preparation and Analysis. Cell samples from each well were lysed
with 500ml 70%methanol containing internal standard, placed on a shaker for 15
minutes, filtered through aWhatman 96-well Unifilter 25-mmMBPP/0.45-mmPP
filter plate, evaporated to dryness, and reconstituted in sample diluent (200 ml,
70% methanol containing 0.1% formic acid). Reconstituted samples were filtered
through aMillipore 0.45-mm filter plate and 5-ml aliquots were analyzed by liquid
chromatography–tandemmass spectrometry as described previously (Slizgi et al.,
2016). In brief, tolvaptan, DM-4103, and DM-4107 were separated chromato-
graphically on a Shimadzu high-performance liquid chromatography system
(LC-10ADVP pumps, SIL-HTc autosampler and a CTO-10 AVP column oven;
Shimadzu, Columbia, MD) with gradient elution. Then tandem mass spectrom-
etry with positive ion electrospray ionization was conducted with a Thermo
Electron TSQQuantumDiscoveryMAX (Thermo Fisher,Waltham,MA) with an
Ion Max electrospray ionization source. The transitions monitored (parent m/z.
product m/z) at unit resolution for tolvaptan, DM-4103, and DM-4107 were
449.2. 252.0, 479.0. 252.0, and 481.0. 252.0, respectively. The assay range
for tolvaptan, DM-4103, and DM-4107 was 0.0025–25 pmol/ml (0.0125–
125 pmol injected on column).
Data Analysis. Protein content was determined by Pierce BCA acid
protein assay kit according to the manufacturer’s protocol (ThermoScientific,
Rockford, IL). Cellular accumulation determined in Ca2+-free HBSS (Accu-
mulation Ca2+-free HBSS) represents the total mass of analyte in the hepatocyte at
the end of the incubation time period. Total accumulation determined in
standard HBSS (Accumulationstandard HBSS) represents the total mass of com-
pound taken up and excreted (cells+bile). The biliary excretion index (BEI) was
calculated using the following equation as reported previously by our laboratory
(Liu et al., 1999):
BEI ð%Þ ¼ Accumulation standard HBSS2 Accumulation Ca2þ2 free HBSS
Accumulationstandard HBSS
 100
ð1Þ
The intracellular concentration of each test compound was calculated by dividing
the mass of compound in cells (Accumulationstandard HBSS) by the intracellular
fluid volume for human hepatocytes (7.6 ml/mg protein; Qualyst Transporter
Solutions Technical Application Bulletin, 2011).
Results and Discussion
Accumulation of Tolvaptan and Metabolites in SCHH. The
accumulation of tolvaptan, DM-4103, and DM-4107 was investigated in
SCHH.Accumulation of tolvaptanwas concentration-dependent after a 10-
minute incubation over the tolvaptan concentration range of 0.15–50 mM
(Fig. 1A). The total (cells+bile) accumulation ranged from ;13 to 3900
pmol/mg protein, whereas the biliary excretion of tolvaptan was negligi-
ble (Fig. 1A). Metabolism of tolvaptan to DM-4103 and DM-4107 was
observed at tolvaptan incubation concentrations greater than 15 mM
and 1.5 mM, respectively (Fig. 1B). Cellular concentrations of tolvaptan,
DM-4103, and DM-4107 also showed a concentration-dependent increase
after a 10-minute incubation of 0.15–50 mM tolvaptan (Fig. 1B). The total
cellular concentration of tolvaptan ranged from ;2 mM to 500 mM and
was greater than the respective incubation concentration (0.15–50 mM).
DM-4103 could not be detected at low tolvaptan incubation concentra-
tions (0.15–1.5 mM). At higher tolvaptan incubation concentrations (15–
50 mM), cellular concentrations of DM-4103 ranged from ;0.16 to
0.19 mM. Concentrations of DM-4107 were higher than DM-4103 and
Fig. 1. Accumulation of tolvaptan, DM-4103, and DM-4107 in SCHH after a 10-
minute incubation in the presence of 4% BSA. (A) Concentration-dependent
accumulation of tolvaptan in standard HBSS (black bars) and Ca2+-free HBSS
(white bars and inset). (B) Hepatocellular concentrations of tolvaptan, DM-4103,
and DM-4107 after a 10-minute incubation of 0.15–50 mM tolvaptan in standard
HBSS. Data are expressed as mean 6 S.D. (n = 1 human liver in triplicate).
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ranged from ;0.15 to 4.26 mM at tolvaptan incubation concentrations of
1.5 to 50 mM, respectively, after a 10-minute incubation (Fig. 1B).
Effect of Inhibitors on the Disposition of Tolvaptan and
Metabolites. The hepatobiliary disposition of tolvaptan, DM-4103,
and DM-4107 was evaluated in SCHH in the presence and absence
of various inhibitors. For these studies, a tolvaptan concentration of
15 mM and incubation time of 10 minutes were selected. Pioglitazone,
verapamil, MK-571, and elacridar at the concentrations tested were
selected as inhibitors of canalicular transporters (e.g., P-gp, MRP2,
BCRP) (Achira et al., 1999; Englund et al., 2014). These compounds
also inhibit CYP3A (IC50: 12.3, 20, 11.3, and 4.9 mM, respectively)
(Achira et al., 1999; Sahi et al., 2003; Englund et al., 2014). Tolvaptan
accumulation was not markedly altered by 50 mM pioglitazone,
verapamil, MK-571, or 10 mM elacridar (data not shown), consistent
with the finding that the biliary excretion of tolvaptan was negligible
in the present study design. Pioglitazone, verapamil, MK-571, and
elacridar reduced mean DM-4107 accumulation by 45.6, 79.8, 94.5,
and 23.0% relative to control, respectively (Fig. 2), consistent with
CYP3A inhibition. DM-4103 concentrations were below the limit of
detection when tolvaptan was coincubated with pioglitazone, verapamil,
MK-571 and elacridar, probably due to reduced tolvaptan metabolism.
Effect of Tolvaptan on the Disposition of Transporter Probes.
The effects of tolvaptan coincubation for 10minutes on the hepatobiliary
disposition of select transporter substrates in SCHH were evaluated.
TCA cell+bile accumulation and BEI were decreased as tolvaptan
concentrations increased (Fig. 3A). These data are consistent with recent
findings that tolvaptan and DM-4103 can inhibit BSEP transport in
membrane vesicles from Sf9 insect cells expressing human BSEP (IC50
of 31.6 and 4.15 mM, respectively; Slizgi et al., 2016). Although the
cellular accumulation of tolvaptan is high when 15 mM tolvaptan is
incubated with SCHH for 10 minutes in the presence of 4% BSA in the
incubation medium (Fig. 1), the cellular unbound concentration of
tolvaptan should be less than the reported IC50 values for BSEP
inhibition considering that the protein binding of tolvaptan is 98.5%
in human plasma (Furukawa et al., 2011). On the basis of these data,
tolvaptan-mediated BSEP inhibition should be low at typical clinical
tolvaptan doses in patients with normal bile acid homeostasis. How-
ever, in patients with disease or polymorphisms that disrupt bile acid
homeostasis, BSEP inhibition at very high clinical doses of tolvaptan
may result in an adverse outcome.
Although tolvaptan can inhibit NTCP-mediated TCA uptake at high
concentrations, unbound tolvaptan concentrations in the present studies
were well below the IC50 value of 41.5 mM reported by Slizgi et al.
(2016). Tolvaptan (15 mM) compared with control had no effect on the
cell+bile accumulation of pravastatin (3.66 6 0.50 versus 3.89 6
0.50 pmol/mg protein) or metformin (6.41 6 0.49 versus 6.34 6
0.45pmol/mg protein), or on the cellular accumulation of these probe
substrates. While the cell+bile accumulation of digoxin was not affected
by tolvaptan, cellular accumulation appeared to increase; the BEI of
digoxin decreased by 65.9% compared with control (Fig. 3B), consistent
with P-gp inhibition as reported previously (Shoaf et al., 2011).
In summary, the present study investigated the hepatobiliary dispo-
sition of tolvaptan and metabolites in SCHH, and relevant DDIs.
Tolvaptan was metabolized in SCHH with accumulation of the gen-
erated metabolites DM-4107 and DM-4103. Tolvaptan metabolism in
SCHH was impaired by known CYP3A inhibitors. Tolvaptan and/
or generated metabolites were capable of inhibiting BSEP and P-gp
function on the basis of altered hepatobiliary disposition of probe
substrates in SCHH. These results demonstrate the utility of SCHH for
investigating DDIs in which both the parent compound and generated
metabolites may be involved. However, the in vitro data always need to
be interpreted within the context of clinical data. For tolvaptan, although
the results of the present series of experiments suggest the possibility of
DDIs at higher tolvaptan concentrations, DDIs have not been reported to
date on the basis of clinical data (Bhatt et al., 2014).
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Fig. 2. Effect of inhibitors on generated DM-4107 disposition in SCHH. Total
accumulation (cell + bile) of DM-4107 was quantified after coincubation of 50 mM
pioglitazone, verapamil, and MK-571 or 10 mM elacridar with 15 mM tolvaptan for
10 minutes in the presence of 4% BSA in SCHH. Data are expressed as mean 6
S.D. (n = 1 human liver in triplicate).
Fig. 3. Effect of tolvaptan on the disposition of transporter probes in sandwich-
cultured human hepatocytes. Total accumulation (cell+bile; black bars) and cellular
accumulation (white bars) in SCHH of (A) taurocholate (TCA; 2.5 mM) coincubated
for 10 minutes in the presence of 4% BSA with tolvaptan (0–50 mM), or (B) digoxin
(DIG; 2.5 mM) coincubated for 10 minutes in the presence of 4% BSA with
tolvaptan (15 mM). Data are reported as mean 6 S.D. (n = 1 liver in triplicate).
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